Stummvoll H K, Graf H, Meisinger V
Miner Electrolyte Metab. 1984;10(4):263-6.
The effects of desferrioxamine administration on aluminum kinetics during hemodialysis were studied. Desferrioxamine leads to an increase of plasma aluminum levels in patients on chronic hemodialysis which could be attributed to mobilization of tissue aluminum. The in vivo protein binding of aluminum was found to be 70% after administration of desferrioxamine vs. 80% without a premedication with desferrioxamine, thus greatly enhancing the concentration gradient between free diffusible plasma aluminum and dialysate aluminum. Desferrioxamine therefore leads to increased aluminum removal during hemodialysis and should be considered in the therapy of aluminum toxicity syndromes.
研究了去铁胺给药对血液透析期间铝动力学的影响。去铁胺导致慢性血液透析患者血浆铝水平升高，这可能归因于组织铝的动员。发现给予去铁胺后铝的体内蛋白结合率为70%，而未预先给予去铁胺时为80%，从而大大增强了游离可扩散血浆铝与透析液铝之间的浓度梯度。因此，去铁胺导致血液透析期间铝清除增加，在铝中毒综合征的治疗中应予以考虑。
